• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

在肿瘤诊所实施基于患者就诊时点的戒烟干预措施的成本效益分析。

Cost-effectiveness of point of care smoking cessation interventions in oncology clinics.

机构信息

University of Ottawa Heart Institute, Ottawa, ON, Canada.

University of Ottawa, School of Epidemiology and Public Health, Ottawa, ON, Canada.

出版信息

Br J Cancer. 2024 Oct;131(7):1178-1185. doi: 10.1038/s41416-024-02819-z. Epub 2024 Aug 14.

DOI:10.1038/s41416-024-02819-z
PMID:39143327
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11443138/
Abstract

BACKGROUND

We examined the cost-effectiveness of providing systematic smoking cessation interventions to oncology patients at point-of-care.

METHODS

A decision analytic model was completed from the healthcare payer's perspective and included all incident cancer cases involving patients who smoke in New Brunswick, Canada (n = 1040), cancer site stratifications, and risks of mortality, continued smoking, and cancer treatment failure over one year. Usual care (no cessation support) was compared to the standard Ottawa Model for Smoking Cessation (OMSC) intervention, and to OMSC plus unlimited cost-free stop smoking medication (OMSC + SSM), including nicotine replacement therapy, varenicline, or bupropion. Primary outcomes were incremental cost per quit (ICQ) and incremental cost per cancer treatment failure avoided (ICTFA).

RESULTS

The ICQ was $C143 and ICTFA $C1193 for standard OMSC. The ICQ was $C503 and ICTFA was $C5952 for OMSC + SSM. The number needed to treat (NNT) to produce one quit was 9 for standard OMSC and 4 for OMSC + SSM, and the NNT to avoid one first-line treatment failure was 78 for OMSC and 45 for OMSC + SSM. Both were cost-effective in 100% of 1000 simulations.

CONCLUSIONS

Given the high clinical benefits and low incremental costs, systematic smoking cessation interventions should be a standard component of first-line cancer treatment.

摘要

背景

我们研究了在医疗保健点为肿瘤患者提供系统戒烟干预的成本效益。

方法

从医疗保健支付者的角度完成了决策分析模型,包括涉及新不伦瑞克省(加拿大)吸烟的所有癌症患者(n=1040)、癌症部位分层以及一年内死亡率、持续吸烟和癌症治疗失败风险的所有新癌症病例。将常规护理(无戒烟支持)与标准渥太华戒烟模式(OMSC)干预进行比较,并与 OMSC 加无限量免费戒烟药物(OMSC+SSM)进行比较,包括尼古丁替代疗法、伐尼克兰或安非他酮。主要结果是每戒烟增量成本(ICQ)和每避免一次癌症治疗失败的增量成本(ICTFA)。

结果

标准 OMSC 的 ICQ 为$C143,ICTFA 为$C1193。OMSC+SSM 的 ICQ 为$C503,ICTFA 为$C5952。标准 OMSC 的每治疗一例需要治疗的人数(NNT)为 9,而 OMSC+SSM 的 NNT 为 4,避免一线治疗失败的 NNT 为 78,而 OMSC+SSM 的 NNT 为 45。在 1000 次模拟的 100%中,两者均具有成本效益。

结论

鉴于高临床效益和低增量成本,系统的戒烟干预应该成为一线癌症治疗的标准组成部分。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/de32/11443138/43a32367db46/41416_2024_2819_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/de32/11443138/241aa796f29e/41416_2024_2819_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/de32/11443138/e3c894ae35b2/41416_2024_2819_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/de32/11443138/43a32367db46/41416_2024_2819_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/de32/11443138/241aa796f29e/41416_2024_2819_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/de32/11443138/e3c894ae35b2/41416_2024_2819_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/de32/11443138/43a32367db46/41416_2024_2819_Fig3_HTML.jpg

相似文献

1
Cost-effectiveness of point of care smoking cessation interventions in oncology clinics.在肿瘤诊所实施基于患者就诊时点的戒烟干预措施的成本效益分析。
Br J Cancer. 2024 Oct;131(7):1178-1185. doi: 10.1038/s41416-024-02819-z. Epub 2024 Aug 14.
2
Incremental net monetary benefit of using varenicline for smoking cessation: A systematic review and meta-analysis of economic evaluation studies.使用伐尼克兰戒烟的增量净货币效益:系统评价和经济评估研究的荟萃分析。
Addiction. 2024 Jul;119(7):1188-1202. doi: 10.1111/add.16464. Epub 2024 Mar 22.
3
Cost-utility analysis of smoking cessation to prevent operative complications following elective abdominal colon surgery.戒烟以预防择期腹部结肠手术后手术并发症的成本-效用分析。
Am J Surg. 2018 Dec;216(6):1082-1089. doi: 10.1016/j.amjsurg.2018.08.010. Epub 2018 Aug 29.
4
Cost-Effectiveness Analysis of Smoking Cessation Interventions in the United Kingdom Accounting for Major Neuropsychiatric Adverse Events.英国戒烟干预措施的成本效益分析:考虑主要神经精神不良事件。
Value Health. 2021 Jun;24(6):780-788. doi: 10.1016/j.jval.2020.12.012. Epub 2021 Mar 11.
5
Smoking cessation medicines and e-cigarettes: a systematic review, network meta-analysis and cost-effectiveness analysis.戒烟药物和电子烟:系统评价、网络荟萃分析和成本效益分析。
Health Technol Assess. 2021 Oct;25(59):1-224. doi: 10.3310/hta25590.
6
Economic Evaluation of Enhanced vs Standard Varenicline Treatment for Tobacco Cessation.增强型伐伦克林与标准伐伦克林治疗烟草戒断的经济学评价。
JAMA Netw Open. 2024 Apr 1;7(4):e248727. doi: 10.1001/jamanetworkopen.2024.8727.
7
Cost-effectiveness of real-world administration of tobacco pharmacotherapy in the United States Veterans Health Administration.美国退伍军人事务部真实世界烟草药物治疗管理的成本效益。
Addiction. 2019 Aug;114(8):1436-1445. doi: 10.1111/add.14621. Epub 2019 Jun 10.
8
Varenicline: a pharmacoeconomic review of its use as an aid to smoking cessation.伐仑克林:作为戒烟辅助药物的药物经济学评价。
Pharmacoeconomics. 2010;28(3):231-54. doi: 10.2165/11204380-000000000-00000.
9
Cost effectiveness of varenicline in Belgium, compared with bupropion, nicotine replacement therapy, brief counselling and unaided smoking cessation: a BENESCO Markov cost-effectiveness analysis.在比利时,与安非他酮、尼古丁替代疗法、简短咨询和无辅助戒烟相比,伐尼克兰的成本效益:一项BENESCO马尔可夫成本效益分析。
Clin Drug Investig. 2009;29(10):655-65. doi: 10.2165/11317730-000000000-00000.
10
Cost-effectiveness of varenicline versus bupropion, nicotine-replacement therapy, and unaided cessation in Greece.希腊伐伦克林与安非他酮、尼古丁替代疗法和非药物戒烟的成本效益比较。
Clin Ther. 2012 Aug;34(8):1803-14. doi: 10.1016/j.clinthera.2012.07.002. Epub 2012 Jul 20.

引用本文的文献

1
Treating tobacco dependency in cancer care: essential, cost-effective, and feasible, yet overlooked.在癌症护理中治疗烟草依赖:至关重要、具有成本效益且可行,但却被忽视了。
Br J Cancer. 2025 Apr;132(7):585-586. doi: 10.1038/s41416-025-02957-y. Epub 2025 Feb 14.

本文引用的文献

1
Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: Updated reporting guidance for health economic evaluations.《2022年卫生经济评估报告合并标准》(CHEERS 2022)声明:卫生经济评估的更新报告指南。
Health Policy Open. 2022 Jan 5;3:100063. doi: 10.1016/j.hpopen.2021.100063. eCollection 2022 Dec.
2
Cost-effectiveness of Implementing Smoking Cessation Interventions for Patients With Cancer.实施癌症患者戒烟干预措施的成本效益。
JAMA Netw Open. 2022 Jun 1;5(6):e2216362. doi: 10.1001/jamanetworkopen.2022.16362.
3
Rates of Smoking Cessation at 6 and 12 Months after a Clinical Tobacco Smoking Cessation Intervention in Head and Neck Cancer Patients in Northern Ontario, Canada.
加拿大安大略省北部头颈部癌症患者接受临床戒烟干预后 6 个月和 12 个月的戒烟率。
Curr Oncol. 2022 Mar 2;29(3):1544-1558. doi: 10.3390/curroncol29030130.
4
Health economic analysis for the 'CURE Project' pilot: a hospital-based tobacco dependency treatment service in Greater Manchester.“CURE 项目”试点的健康经济分析:大曼彻斯特地区基于医院的烟草依赖治疗服务。
BMJ Open Respir Res. 2021 Dec;8(1). doi: 10.1136/bmjresp-2021-001105.
5
The Role of Cost-Effectiveness Analysis in Patient-Centered Cancer Care in the Era of Precision Medicine.成本效益分析在精准医学时代以患者为中心的癌症护理中的作用。
Cancers (Basel). 2021 Aug 25;13(17):4272. doi: 10.3390/cancers13174272.
6
Cost-effectiveness of nivolumab in squamous and non-squamous non-small cell lung cancer in Canada and Sweden: an update with 5-year data.加拿大和瑞典的纳武利尤单抗在鳞状和非鳞状非小细胞肺癌中的成本效益:5 年数据更新。
J Med Econ. 2021 Jan-Dec;24(1):607-619. doi: 10.1080/13696998.2021.1917139.
7
Implementation of a systematic tobacco treatment protocol in a surgical outpatient setting: a feasibility study.在外科门诊环境中实施系统的烟草治疗方案:一项可行性研究。
Can J Surg. 2021 Feb 3;64(1):E51-E58. doi: 10.1503/cjs.009919.
8
Smoking status during first-line immunotherapy and chemotherapy in NSCLC patients: A case-control matched analysis from a large multicenter study.一线免疫治疗和化疗期间非小细胞肺癌患者的吸烟状况:一项来自大型多中心研究的病例对照匹配分析。
Thorac Cancer. 2021 Mar;12(6):880-889. doi: 10.1111/1759-7714.13852. Epub 2021 Feb 1.
9
Cost-Effectiveness of Smoking Cessation Interventions in the Lung Cancer Screening Setting: A Simulation Study.肺癌筛查环境下戒烟干预措施的成本效益:一项模拟研究。
J Natl Cancer Inst. 2021 Aug 2;113(8):1065-1073. doi: 10.1093/jnci/djab002.
10
The cost of failed first-line cancer treatment related to continued smoking in Canada.加拿大因持续吸烟导致一线癌症治疗失败的成本。
Curr Oncol. 2020 Dec;27(6):307-312. doi: 10.3747/co.27.5951. Epub 2020 Dec 1.